Article Figures & Data
Figures
- Fig. 1.
Tumor invasiveness. A–F, osteosarcomas in trp53+/tm1 mice and their metastases in lungs and liver. A, primary tumor in CD44+/+ background; B, representative lung metastasis in CD44+/+ background; C, representative liver metastasis in CD44+/+ background; D, primary tumor in CD44−/− background; E, only metastasis detected in CD44−/− background (H&E); F, incidence of metastases in livers and lungs from osteosarcoma bearing mice.
- Fig. 2.
Expression of CD44. A and B, immunohistochemistry for CD44 expression in osteosarcomas from a trp53+/tm1 CD44+/+ (A) and a trp53+/tm1 CD44−/− mouse (B). In C and D, typing of the mice was performed by flow cytometry with FITC-anti-CD44 on spleen cells and lymph node cells (data not shown) and by PCR on genomic DNA with published primers (11) ; C, CD44+/+; D, CD44−/−.
- Fig. 3.
Intestinal polyps caused by the min mutation of the APC gene are not invasive. Histology of representative intestinal polyps from APC+/min mice. The largest polyp from each intestine was sectioned in the middle and stained with H&E for histological assessment of signs for malignancy. Regardless of the presence of the CD44 gene, the basement membrane remains intact (arrows). A, CD44+/+; B, CD44−/−.
- Fig. 4.
Tumor incidence. The numbers of intestinal polyps were counted in APC+/min mice at the end of their life span (average 209 days for 10 APC+/minCD44+/+ mice and 236 days for 15 APC+/minCD44−/− mice). The incidence of spontaneous polyps was assessed at an average of 433 days for 3 APC+/+CD44+/+ mice and 437 days for 3 APC+/+CD44−/− mice. Symbols, individual data points; mean values are presented as horizontal lines.
- Fig. 5.
Carcinomas in mice with one mutant p53 allele. Histology of sporadic carcinomas in trp53+/tm1 mice, including a squamous cell carcinoma (CD44+/+; top) and a lung carcinoma (CD44−/−; bottom). The slides are stained with H&E.
- Fig. 6.
Kaplan-Meier survival curves. A, survival of APC+/min mice with wild-type (▪) or deleted (•) CD44 gene. All APC+/+ mice survived the 420-day period of observation. B, survival of trp53+/tm1 mice. Within 600 days, mice with the trp53+/tm1 genotype succumbed to various tumors independently of their CD44 status, leading to survival of 4% or 1 mouse (CD44+/+, ▵) and 23% or 6 mice (CD44−/−, ▪). Control mice with the wild-type trp53 gene had survival rates of 87% or 14 mice (CD44+/+, ▴) and 83% or 30 mice (CD44−/−, □).
Tables
- Table 1
Characterization of solid tumors in trp53+/tm1 mice. Incidence, associated life span, and tumor weight at the time of death are specified for each histologic type of sarcoma for CD44+/+ and CD44−/− genetic background. Life span and tumor weight are indicated as mean ± standard error.
Tumor Incidence Life span Weight Osteosarcoma trp53CD44 6 (25%) 5 f, 1 ma 532 ± 30 days P > 0.05 7.7 ± 2.4 grams P > 0.05 trp53CD44 4 (15%) 3 f, 1 m 467 ± 56 days 6.1 ± 1.7 grams Fibrosarcoma trp53CD44 7 (29%) 4 f, 3 m 410 ± 23 days P > 0.05 21.9 ± 5.0 grams P > 0.05 trp53CD44 7 (27%) 5 f, 2 m 403 ± 30 days 12.3 ± 2.9 grams Hemangiosarcoma trp53CD44 3 (12%) 2 f, 1 m 304 ± 51 days 10.7 ± 8.1 grams trp53CD44 0 (0%) trp53CD44 1 (3%) 1 m 595 days 2.9 grams Histiocytic sarcoma trp53CD44 2 (8%) 2 m 589/590 days trp53CD44 1 (4%) 1 f 420 days trp53CD44 1 (6%) 1 m 600 days -
a f = female; m = male.
-
Volume 62, Issue 8
